A New Dawn for Merrimack: Former Anheuser-Busch Brewery Site Acquired by Biotech Innovator United Therapeutics

A significant chapter has closed, and a vibrant new one is undoubtedly beginning for the sprawling, nearly 300-acre former Anheuser-Busch brewery in Merrimack, New Hampshire. After decades as a local landmark and a major employer, the iconic site has officially changed hands, sold to United Therapeutics Corporation for a cool $47 million – or perhaps even $47.5 million, depending on which deed record you check from the Hillsborough County Registry. This momentous transaction, which took place around early September 2026, truly signals a transformation for the region, paving the way for a future rooted in biotechnology rather than beer.

For 55 years, the Anheuser-Busch facility at 221 Daniel Webster Highway was more than just a brewery; it was a cornerstone of the Merrimack community. Locals will fondly recall the industrial brewing operations, the bustling distribution hub, the tasting room, and those delightful beer gardens. And who could forget the majestic Budweiser Clydesdales, who called the site home until 2018? It was a place that generated substantial economic activity, contributing over $780,000 annually in property taxes to the town and an additional $1 million to $1.5 million in annual wastewater utility fees. When Anheuser-Busch made the tough decision to close the facility earlier this year, citing a nationwide supply chain restructuring, it left a palpable void, a bit of a bittersweet moment for everyone involved.

Enter United Therapeutics Corporation. This isn't just any buyer; it's a biotechnology powerhouse, a public benefit corporation headquartered in Silver Spring, Maryland, with a truly inspiring mission. Founded in 1996 by Martine Rothblatt – yes, the same visionary who also founded Sirius XM – United Therapeutics specializes in developing groundbreaking therapies for rare, chronic conditions. Think Pulmonary Arterial Hypertension (PAH), for example. Their product portfolio is impressive, boasting names like Tyvaso, Remodulin, Orenitram, Adcirca, and Unituxin.

But what really sets United Therapeutics apart is their pioneering work in bioengineered organ manufacturing. They're literally at the forefront of gene-edited porcine organ transplant technologies, also known as xenotransplantation, and pushing the boundaries of 3D bioprinting. This is cutting-edge stuff, and frankly, it's quite exciting to think about what they might bring to Merrimack. The company already has a footprint in New Hampshire, having established a facility on Commercial Street in Manchester back in 2023. So, they're clearly invested in the state.

What does this mean for Merrimack? Well, the expectation is that this acquisition will usher in hundreds of high-paying jobs, a welcome boost to the local economy. While the specific construction plans, architectural designs, and a precise timeline for redeveloping this vast industrial campus haven't been fully disclosed just yet, the promise is significant. It's a fundamental shift from the brewing traditions of the past to the innovative, life-saving potential of the future. With United Therapeutics' market capitalization sitting at a robust $20.5 billion (according to NASDAQ), their investment in Merrimack truly represents a monumental vote of confidence in New Hampshire's burgeoning high-tech sector.